Caveolin 1 protein expression in renal cell carcinoma predicts survival

BMC Urology

Volumn 11, Issue , 2011, Pages

  Steffens, Sandra ^a   Schrader, Andres J ^b   Blasig, Hanna ^a   Vetter, Gesa ^a   Eggers, Hendrik ^a   Tränkenschuh, Wolfgang ^a   Kuczyk, Markus A ^a   Serth, Jürgen ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF ULM MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 1; TUMOR MARKER; TUMOR PROTEIN;

ADULT; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR DIFFERENTIATION; BLOOD; GERMANY; KIDNEY TUMOR; METHODOLOGY; MIDDLE AGED; MORTALITY; PREVALENCE; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SURVIVAL; SURVIVAL RATE;

CARCINOMA, RENAL CELL; CAVEOLIN 1; FEMALE; GERMANY; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PREVALENCE; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 82755195817     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-11-25     Document Type: Article

References (36)

1. [Gender-specific characteristics and survival of renal cell carcinoma]. Schrader AJ, Sevinc S, Olbert PJ, Hegele A, Varga Z, Hofmann R, Der Urologe Ausg 2008 47 9 1182, 1184 1186
2. Differential expression of caveolin-1 in renal neoplasms. Tamaskar I, Choueiri TK, Sercia L, Rini B, Bukowski R, Zhou M, Cancer 2007 110 4 776 782 (Pubitemid 47257654)
3. Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. Engelman JA, Wykoff CC, Yasuhara S, Song KS, Okamoto T, Lisanti MP, The Journal of biological chemistry 1997 272 26 16374 16381 (Pubitemid 27276462)
4. Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav-1, -2, and -3). Cav-1 and Cav-2 genes map to a known tumor suppressor locus (6-A2/7q31). Engelman JA, Zhang XL, Galbiati F, Lisanti MP, FEBS letters 1998 429 3 330 336 (Pubitemid 28300386)
5. Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. Engelman JA, Zhang XL, Lisanti MP, FEBS letters 1998 436 3 403 410 (Pubitemid 28482971)
6. Sequence and detailed organization of the human caveolin-1 and -2 genes located near the D7S522 locus (7q31.1). Methylation of a CpG island in the 5' promoter region of the caveolin-1 gene in human breast cancer cell lines. Engelman JA, Zhang XL, Lisanti MP, FEBS letters 1999 448 2-3 221 230 (Pubitemid 29168492)
7. Cholesterol depletion of caveolae causes hyperactivation of extracellular signal-related kinase (ERK). Furuchi T, Anderson RG, The Journal of biological chemistry 1998 273 33 21099 21104 (Pubitemid 28385396)
8. Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. Galbiati F, Volonte D, Engelman JA, Watanabe G, Burk R, Pestell RG, Lisanti MP, The EMBO journal 1998 17 22 6633 6648 (Pubitemid 28521797)
9. Reduction of caveolin and caveolae in oncogenically transformed cells. Koleske AJ, Baltimore D, Lisanti MP, Proceedings of the National Academy of Sciences of the United States of America 1995 92 5 1381 1385
10. Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Lee SW, Reimer CL, Oh P, Campbell DB, Schnitzer JE, Oncogene 1998 16 11 1391 1397 (Pubitemid 28151846)
11. RNA genetics of breast cancer: maspin as paradigm. Sager R, Sheng S, Anisowicz A, Sotiropoulou G, Zou Z, Stenman G, Swisshelm K, Chen Z, Hendrix MJ, Pemberton P, et al. Cold Spring Harbor symposia on quantitative biology 1994 59 537 546
12. Identification, sequence, and expression of caveolin-2 defines a caveolin gene family. Scherer PE, Okamoto T, Chun M, Nishimoto I, Lodish HF, Lisanti MP, Proceedings of the National Academy of Sciences of the United States of America 1996 93 1 131 135 (Pubitemid 26041482)
13. Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. Campbell L, Gumbleton M, Griffiths DF, British journal of cancer 2003 89 10 1909 1913 (Pubitemid 37533269)
14. Rapid and large-scale transition of new tumor biomarkers to clinical biopsy material by innovative tissue microarray systems. Mengel M, Kreipe H, von Wasielewski R, Appl Immunohistochem Mol Morphol 2003 11 3 261 268 (Pubitemid 37082064)
15. TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Guinan P, Sobin LH, Algaba F, Badellino F, Kameyama S, MacLennan G, Novick A, Cancer 1997 80 5 992 993
16. Prognostic significance of morphologic parameters in renal cell carcinoma. Fuhrman SA, Lasky LC, Limas C, The American journal of surgical pathology 1982 6 7 655 663 (Pubitemid 13234762)
17. Pathology, biology, and clinical staging of renal cell carcinoma. Stenzl A, deKernion JB, Seminars in oncology 1989 16 1 Suppl 1 3 11 (Pubitemid 19086385)
18. Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF Jr, Cancer 1997 80 11 2109 2119 (Pubitemid 27506024)
19. Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions. Merseburger AS, Hennenlotter J, Simon P, Muller CC, Kuhs U, Knuchel-Clarke R, Moul JW, Stenzl A, Kuczyk MA, Oncol Rep 2006 16 1 79 83
20. Involvement of decreased Galectin-3 expression in the pathogenesis and progression of prostate cancer. Merseburger AS, Kramer MW, Hennenlotter J, Simon P, Knapp J, Hartmann JT, Stenzl A, Serth J, Kuczyk MA, The Prostate 2008 68 1 72 77
21. The involvement of altered corticotropin releasing factor receptor 2 expression in prostate cancer due to alteration of anti-angiogenic signaling pathways. Tezval H, Jurk S, Atschekzei F, Serth J, Kuczyk MA, Merseburger AS, The Prostate 2008
22. RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis. Peters I, Rehmet K, Wilke N, Kuczyk MA, Hennenlotter J, Eilers T, Machtens S, Jonas U, Serth J, Molecular cancer 2007 6 49
23. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Yang G, Truong LD, Wheeler TM, Thompson TC, Cancer research 1999 59 22 5719 5723
24. Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Bender FC, Reymond MA, Bron C, Quest AF, Cancer research 2000 60 20 5870 5878
25. Reduction of caveolin 1 gene expression in lung carcinoma cell lines. Racine C, Belanger M, Hirabayashi H, Boucher M, Chakir J, Couet J, Biochemical and biophysical research communications 1999 255 3 580 586 (Pubitemid 29294841)
26. Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Wiechen K, Diatchenko L, Agoulnik A, Scharff KM, Schober H, Arlt K, Zhumabayeva B, Siebert PD, Dietel M, Schafer R, et al. The American journal of pathology 2001 159 5 1635 1643 (Pubitemid 33062506)
27. Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. Wiechen K, Sers C, Agoulnik A, Arlt K, Dietel M, Schlag PM, Schneider U, The American journal of pathology 2001 158 3 833 839 (Pubitemid 32221776)
28. Impact of caveolin-1 expression on clinicopathological parameters in renal cell carcinoma. Horiguchi A, Asano T, Asakuma J, Asano T, Sumitomo M, Hayakawa M, The Journal of urology 2004 172 2 718 722 (Pubitemid 38900248)
29. Caveolin 1 mRNA is overexpressed in malignant renal tissue and might serve as a novel diagnostic marker for renal cancer. Waalkes S, Eggers H, Blasig H, Atschekzei F, Kramer MW, Hennenlotter J, Trankenschuh W, Stenzl A, Serth J, Schrader AJ, et al. Biomarkers in medicine 5 2 219 225
30. Can renal oncocytoma be differentiated from its renal mimics? The utility of anti-mitochondrial, caveolin 1, CD63 and cytokeratin 14 antibodies in the differential diagnosis. Mete O, Kilicaslan I, Gulluoglu MG, Uysal V, Virchows Arch 2005 447 6 938 946 (Pubitemid 41719548)
31. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Tahir SA, Yang G, Ebara S, Timme TL, Satoh T, Li L, Goltsov A, Ittmann M, Morrisett JD, Thompson TC, Cancer research 2001 61 10 3882 3885 (Pubitemid 32720945)
32. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Tahir SA, Frolov A, Hayes TG, Mims MP, Miles BJ, Lerner SP, Wheeler TM, Ayala G, Thompson TC, Kadmon D, Clin Cancer Res 2006 12 16 4872 4875 (Pubitemid 44338573)
33. MMP-2 colocalizes with caveolae on the surface of endothelial cells. Puyraimond A, Fridman R, Lemesle M, Arbeille B, Menashi S, Experimental cell research 2001 262 1 28 36 (Pubitemid 32989005)
34. Multiple mutations and cancer. Loeb LA, Loeb KR, Anderson JP, Proceedings of the National Academy of Sciences of the United States of America 2003 100 3 776 781 (Pubitemid 36183906)
35. Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma. Campbell L, Jasani B, Edwards K, Gumbleton M, Griffiths DF, British journal of cancer 2008 98 5 931 940 (Pubitemid 351341603)
36. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. Kondagunta GV, Drucker B, Schwartz L, Bacik J, Marion S, Russo P, Mazumdar M, Motzer RJ, J Clin Oncol 2004 22 18 3720 3725 (Pubitemid 41095212)